U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C5H7NO3
Molecular Weight 129.114
Optical Activity ( - )
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PIDOLIC ACID

SMILES

OC(=O)[C@@H]1CCC(=O)N1

InChI

InChIKey=ODHCTXKNWHHXJC-VKHMYHEASA-N
InChI=1S/C5H7NO3/c7-4-2-1-3(6-4)5(8)9/h3H,1-2H2,(H,6,7)(H,8,9)/t3-/m0/s1

HIDE SMILES / InChI

Molecular Formula C5H7NO3
Molecular Weight 129.114
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Zinc Pidolate (Zinc PCA) is a topical skin product with purifying, astingent, anti-inflammatory, antiseptic activity. It has long been used as a cosmetic ingredient, because of its astringent and anti-microbial properties. Zinc Pidolate has also being shown to be effective against halitosis. Zinc PCA prevents the UV-induced MMP-1 production in vitro by suppressing the activation of AP-1. Zinc PCA was also able to enhance type I collagen synthesis in NHDFs, by increasing the expression of the mRNA encoding the ascorbic acid transporter SVCT2 in non-UV irradiated NHDFs, which suggests its promising effect against not only photoaged skin but also for the simple atrophic change of intrinsic skin ageing. Zinc PCA is able to suppress sebum secretion by inhibiting 5-α reductase in hyperseborrhea, to suppress body odor by forming zinc salts with short-chain fatty acids, to suppress wrinkles by inhibiting AP-1 to and inhibit bacterial growth including acne related Propionibacterium acnes.

CNS Activity

Curator's Comment: Known to penetrate blood-brain barrier in rats. Is produced naturally in human brain

Originator

Sources: Haitinger, L.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
CLEANSING FOAMING GEL ACNE PRO SKIN- zinc pidolate gel

Approved Use

Lange Gel will turn into foam, during application. It will cleanse skin thoroughly without any dryness effect, in order to avoid hyperseboohea phenomenon, a main cause of acne.

Launch Date

2012
Primary
Unknown

Approved Use

Unknown
Primary
EcoCare™ Zinclean

Approved Use

Use in anti-dandruff shampoos
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
The X-ray crystal structure of pyrrolidone-carboxylate peptidase from hyperthermophilic archaea Pyrococcus horikoshii.
2002
Expression and prognostic significance of lysozyme in male breast cancer.
2002
Continuous spectrometric assays for glutaminyl cyclase activity.
2002 Apr 1
Spectrophotometric assays for L-lysine alpha-oxidase and gamma-glutamylamine cyclotransferase.
2002 Apr 15
CLAC: a novel Alzheimer amyloid plaque component derived from a transmembrane precursor, CLAC-P/collagen type XXV.
2002 Apr 2
Complete structure of an increasing capillary permeability protein (ICPP) purified from Vipera lebetina venom. ICPP is angiogenic via vascular endothelial growth factor receptor signalling.
2002 Aug 16
Generation of amyloid beta peptide with pyroglutamate at position 3 in primary cortical neurons.
2002 Jul 12
Allatostatins of the tiger prawn, Penaeus monodon (Crustacea: Penaeidea).
2002 Jun
Stereoselective total syntheses of the racemic form and the natural enantiomer of the marine alkaloid lepadiformine via a novel N-acyliminium ion/allylsilane spirocyclization strategy.
2002 Jun 14
Two novel antifungal peptides distinct with a five-disulfide motif from the bark of Eucommia ulmoides Oliv.
2002 Jun 19
Pseudopeptide foldamers: the homo-oligomers of pyroglutamic acid.
2002 Jun 3
[Effect of a drug composition containing pyroglutamic acid and pyrrolidone on the cerebral circulation].
2002 May-Jun
Fluorometric assay using naphthylamide substrates for assessing novel venom peptidase activities.
2002 Nov
Synthesis and preliminary evaluation of trans-3,4-conformationally-restricted glutamate and pyroglutamate analogues as novel EAAT2 inhibitors.
2002 Nov 4
Methacrylate derivatives incorporating pyroglutamic acid.
2002 Nov-Dec
Production of pyroglutamic acid by thermophilic lactic acid bacteria in hard-cooked mini-cheeses.
2002 Oct
Heterologous expression and characterization of human glutaminyl cyclase: evidence for a disulfide bond with importance for catalytic activity.
2002 Sep 3
Stereoselective synthesis of dipeptide beta-turn mimetics: 7-benzyl and 8-phenyl substituted azabicyclo[4.3.0]nonane amino acid esters.
2002 Sep 6
Characterization and sequence of tomato 2S seed albumin: a storage protein with sequence similarities to the fruit lectin.
2003 Apr
Pigment-epithelium-derived factor (PEDF) occurs at a physiologically relevant concentration in human blood: purification and characterization.
2003 Aug 15
Refolding of amphioxus insulin-like peptide: implications of a bifurcating evolution of the different folding behavior of insulin and insulin-like growth factor 1.
2003 Aug 19
Beta-lactams as versatile synthons for homochiral ibotenate analogues with potential for activity at glutamate receptors.
2003 Aug 7
Solution structure of the cytotoxic RNase 4 from oocytes of bullfrog Rana catesbeiana.
2003 Feb 28
Isolation and identification of indigestible pyroglutamyl peptides in an enzymatic hydrolysate of wheat gluten prepared on an industrial scale.
2003 Jan 1
[Neuroprotective properties of pyroglutamic acid in combination with pyrrolidone].
2003 Jan-Feb
Characterization of a new bradykinin-potentiating peptide (TmF) from Trimeresurus mucrosquamatus.
2003 Jul
Pyrrolidinones derived from (S)-pyroglutamic acid: penmacric acid and analogues.
2003 Jul 7
2,5-Disubstituted pyrrolidines: versatile regioselective and diastereoselective synthesis by enamine reduction and subsequent alkylation.
2003 Jun 7
Reinvestigation of the proposed folding and self-association of the Neuropeptide Head Activator.
2003 Mar
[Evolution of the neuroprotection concept].
2003 Mar-Apr
[Oleyl pyroglutamate for use as transdermal enhancer and its enhancing mechanism].
2003 May
Proinsulin C-peptide and its C-terminal pentapeptide: degradation in human serum and Schiff base formation with subsequent CO2 incorporation.
2003 May
[Characteristics of pyrrolidone pharmacokinetics in rats].
2003 Nov-Dec
Structural characterization of native mouse zona pellucida proteins using mass spectrometry.
2003 Sep 5
Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions.
2004 Apr 9
Glutamine in commercial liquid nutritional products.
2004 Aug 11
Toward the synthesis of pyroglutamate lauroyl ester: biocatalysis versus chemical catalysis.
2004 Feb
Stabilization of peptide guinea pig myelin basic protein 72-85 by N-terminal acetylation-implications for immunological studies.
2004 Feb
Human glutaminyl cyclase and bacterial zinc aminopeptidase share a common fold and active site.
2004 Feb 10
Unexplained metabolic acidosis in critically ill patients: the role of pyroglutamic acid.
2004 Mar
Synthesis of (2S,3R)-[3',3',3'-2H3]-valine and (2S,3S)-4-fluorovaline.
2004 May 7
The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography-micro-electrospray ionization-tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent.
2004 Sep 21
The computer modelling of human TRH receptor, TRH and TRH-like peptides.
2005
Formation of extracellular glutamate from glutamine: exclusion of pyroglutamate as an intermediate.
2005 Aug 2
Stereoselective synthesis of conformationally constrained omega-amino acid analogues from pyroglutamic acid.
2005 Aug 7
Physiological and pathological aspects of GSH metabolism.
2005 Feb
CLPM: a cross-linked peptide mapping algorithm for mass spectrometric analysis.
2005 Jul 15
Total synthesis of pinnamine and anatoxin-a via a common intermediate. A caveat on the anatoxin-a endgame.
2005 Jul 8
Bromophenols coupled with derivatives of amino acids and nucleosides from the red alga Rhodomela confervoides.
2005 May
Synthesis of 1,3-dioxo-hexahydropyrido[1,2-c][1,3]diazepine carboxylates, a new bicyclic skeleton formed by ring expansion-RCM methodology.
2005 Sep 21
Patents

Sample Use Guides

In Vivo Use Guide
Sources: Topical, as a compontent of lotions, creams and other cosmetic products.
Topical, as a compontent of lotions, creams and other cosmetic products.
Route of Administration: Topical
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Wed Apr 02 07:52:53 GMT 2025
Edited
by admin
on Wed Apr 02 07:52:53 GMT 2025
Record UNII
SZB83O1W42
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PCA
INCI  
INCI  
Preferred Name English
PIDOLIC ACID
INN   WHO-DD  
INN  
Official Name English
GLP
Common Name English
L-PYROGLUTAMIC ACID
MI  
Common Name English
PYROGLUTAMIC ACID
Common Name English
5-OXO-L-PROLINE
Systematic Name English
AJIDEW A-100
Brand Name English
Pidolic acid [WHO-DD]
Common Name English
PYROGLUTAMIC ACID, L-
Common Name English
L-PYRROLIDONE CARBOXYLIC ACID
Common Name English
5-L-OXOPROLINE
Common Name English
5-OXOPROLINE
Common Name English
L-PCA
Common Name English
PYROGLUTAMATE
Common Name English
PYROGLU
Common Name English
pidolic acid [INN]
Common Name English
PIDOLIDONE
Brand Name English
L-PYROGLUTAMIC ACID [MI]
Common Name English
5-OXO-2-PYRROLIDINECARBOXYLIC ACID
Systematic Name English
(-)-2-PYRROLIDONE-5-CARBOXYLIC ACID
Systematic Name English
PYROGLUTAMIC ACID [USP-RS]
Common Name English
GLUTIMIC ACID
Common Name English
NSC-143034
Code English
NSC-760414
Code English
Classification Tree Code System Code
LOINC 75089-3
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
LOINC 13700-0
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
DSLD 2731 (Number of products:44)
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
NCI_THESAURUS C29703
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
LOINC 29872-9
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
LOINC 29522-0
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
LOINC 53394-3
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
LOINC 53232-5
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
LOINC 43633-7
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
EU-Orphan Drug EU/3/16/1673
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
Code System Code Type Description
NSC
760414
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
PRIMARY
EPA CompTox
DTXSID6046260
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
PRIMARY
NSC
143034
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
PRIMARY
CHEBI
16010
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
PRIMARY
RXCUI
155060
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
PRIMARY RxNorm
WIKIPEDIA
PYROGLUTAMIC ACID
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
PRIMARY
CHEBI
58402
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
PRIMARY
RS_ITEM_NUM
1589029
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
PRIMARY
CHEBI
18183
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
PRIMARY
MERCK INDEX
m9383
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
PRIMARY Merck Index
INN
4079
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
PRIMARY
CAS
98-79-3
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
PRIMARY
CHEBI
30652
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
PRIMARY
DAILYMED
SZB83O1W42
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
PRIMARY
PUBCHEM
7405
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
PRIMARY
DRUG BANK
DB03088
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
PRIMARY
SMS_ID
100000081944
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
PRIMARY
ECHA (EC/EINECS)
202-700-3
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
PRIMARY
EVMPD
SUB09825MIG
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
PRIMARY
CHEBI
57606
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
PRIMARY
NCI_THESAURUS
C82933
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
PRIMARY
FDA UNII
SZB83O1W42
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
PRIMARY
ChEMBL
CHEMBL284718
Created by admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY